阿斯巴拉金依赖是一种可针对的代谢脆弱性,在TP53-改变的割耐药前列腺癌中
Young A Yoo1,2, Songhua Quan1, William Yang1
1Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Cancer research
|July 3, 2024
概括
由于阿斯合成酶 (ASNS) 表达的增加,TP53改变的前列腺癌依赖于阿斯巴拉金 (Asn) 合成. 向阿斯恩生产为抵抗割的前列腺癌提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 癌症生物学 癌症生物学
背景情况:
- TP53瘤抑制剂的改变在致命的割抵抗性前列腺癌 (CRPC) 中很常见.
- 目前对TP53-改变的CRPC的治疗方法有限.
- 前列腺癌的进展涉及代谢适应.
研究的目的:
- 调查TP53-改变的CRPC的代谢依赖性.
- 为了确定TP53改变的CRPC的治疗点.
主要方法:
- 进行了转录组和代谢组分析.
- 研究了ASNS表达及其由TP53调节.
- 评估了阿斯巴拉金限制和补充对CRPC细胞的影响.
- 测试了阿斯巴拉金生物合成的药理抑制剂.
主要成果:
- 改变TP53的CRPC表现出对阿斯巴拉金 (Asn) 的依赖性增加,并过度表达Asn合成酶 (ASNS).
- 丢失或突变TP53通过直接转录激活和mTORC1-介导ATF4诱导调节ASNS.
- 带有TP53变化的CRPC细胞对通过ASNS敲击或L-asparaginase治疗的Asn限制敏感.
- 抑制Asn生物合成途径显著损害了CRPC的生长.
结论:
- 通过ASNS介导的Asn生物合成是TP53改变的CRPC中关键的代谢适应和合成脆弱性.
- 通过抑制细胞内生物合成或耗尽细胞外Asn来向Asn生产,代表了具有TP53改变的CRPC的一个有前途的治疗策略.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


